Results 161 to 170 of about 104,861 (298)

Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum-Sensitive Ovarian Cancer: A Retrospective Study. [PDF]

Cancer Med
Zhang X, Wang Z, Gu Y, Fang H, Wang Y, Fang C, Wu N.   +6 more
europepmc   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications. [PDF]

Transl Oncol
Li J, Mu D, Li J, Lan M, Wu W, Zhang S, Dai Y.   +6 more
europepmc   +1 more source

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

Epigallocatechin‐3‐Gallate Suppresses Glioma by Targeting Integrin αvβ3/FAK/ERK Signaling Axis and Matrix Metalloproteinases

Phytotherapy Research, EarlyView.
EGCG suppresses glioma progression by targeting integrin αvβ3/FAK/ERK signaling and inhibiting MMP‐2/MMP‐9‐mediated ECM degradation, thereby blocking proliferation, migration, invasion, and promoting apoptosis. ABSTRACT Epigallocatechin‐3‐gallate (EGCG), the most abundant and biologically active catechin in green tea, has been widely reported to ...
Rui Sun, Yonghan Pan, Ning Yang, Bing Kang, Hong Xiao, Xianglong Tang, Taiping Li, Mengjie Zhao   +7 more
wiley   +1 more source

PARPs and PARP inhibitors: molecular mechanisms and clinical applications. [PDF]

Mol Biomed
Wang F, Guo Z, Carr MJ, Shi W.
europepmc   +1 more source

Natural Products as Modulators of ABC Transporters in Breast Cancer

Phytotherapy Research, EarlyView.
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan, Reyhaneh Farghadani, Ammu K. Radhakrishnan   +2 more
wiley   +1 more source

Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective. [PDF]

Biomark Res
Xiang J, Li J, Guo Z, Wu J, Ma D, Xu H, Shang T, Pu P, Cong L, Zhou R, Wang X, Yu Y, Liu J.   +12 more
europepmc   +1 more source